<DOC>
	<DOCNO>NCT00574132</DOCNO>
	<brief_summary>This multicenter , double-blind , placebo control , randomize , outpatient multiple dose study male female patient age 50 less 89 year mild moderate AD . Approximately 230 study site US Canada 35 site outside North America involve . Patients randomize receive either bapineuzumab placebo . Each patient 's participation last approximately 1.5 year . Bapineuzumab humanize monoclonal antibody , bind clear beta amyloid peptide , design provide antibody beta amyloid directly patient .</brief_summary>
	<brief_title>Bapineuzumab Patients With Mild Moderate Alzheimer 's Disease ( ApoE4 Non-Carrier )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable AD Age 50 less 89 MiniMental Status Exam score 1626 inclusive Brain magnetic resonance imaging ( MRI ) scan consistent diagnosis AD Stable dose medication ( cholinesterase inhibitor memantine allow ) Caregiver able attend clinic visit patient Significant neurological disease AD Major psychiatric disorder Significant systemic illness History stroke seizure , autoimmune disease , myocardial infarction within last 2 year Smoking great 20 cigarette per day Anticonvulsants , antiParkinson 's , anticoagulant , narcotic medication Prior treatment experimental immunotherapeutics vaccine AD Women childbearing potential Presence pacemaker , CSF shunt , foreign metal object eye , skin body</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>